Page last updated: 2024-10-23

aspirin and Dyslipidemia

aspirin has been researched along with Dyslipidemia in 49 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin."9.22Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016)
"A prospective, clinical trial of 35 patients with mixed dyslipidemia who were treated with niacin-ER and SV."9.14Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010)
"Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia."9.14Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. ( Jiang, P; Kashyap, ML; Krause, SL; Lewin, AJ; Padley, RJ; Thakkar, RB, 2009)
"Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing."8.86A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010)
"Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia."7.96Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020)
"The effect of prior use of aspirin (ASA) on the onset of acute coronary syndrome (ACS) has not been clarified."7.85Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. ( Araki, M; Hada, M; Hamaya, R; Hoshino, M; Ichijo, S; Kakuta, T; Kanaji, Y; Kanno, Y; Lee, T; Matsuda, J; Murai, T; Niida, T; Usui, E; Yonetsu, T, 2017)
"To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia."7.83Effects of low-dose aspirin in subjects with dyslipidemia. ( Chen, J; Lou, G; Xia, Y, 2016)
"To study whether effect of aspirin plus low-dose diethylstilbestrol is more effective and safer than high diethylstilbestrol dose alone on prevention of ovariectomy-induced osteopenia and dyslipidemia."7.79Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. ( Cui, L; Huang, JP; Lin, SE; Wu, LZ; Wu, T, 2013)
"A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin."5.22Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016)
"Once-daily, low-dose aspirin did not significantly reduce the risk of the composite outcome of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction among Japanese patients 60 years or older with atherosclerotic risk factors."5.19Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2014)
"Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia."5.14Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. ( Jiang, P; Kashyap, ML; Krause, SL; Lewin, AJ; Padley, RJ; Thakkar, RB, 2009)
"A prospective, clinical trial of 35 patients with mixed dyslipidemia who were treated with niacin-ER and SV."5.14Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010)
"The Japanese Primary Prevention Project (JPPP) is a multicenter, open-label, randomized, parallel-group trial that is evaluating primary prevention with low-dose aspirin in Japanese patients aged 60 to 85 years with hypertension, dyslipidemia, or diabetes mellitus."5.14Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamada, N; Yamazaki, T; Yokoyama, K, 2010)
"Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing."4.86A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010)
" Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity."4.83Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006)
"Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia."3.96Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020)
"We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project."3.91Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019)
" Recommendations address diagnosis and treatment of cardiovascular risk factors (hypertension and dyslipidemia), aspirin use, screening for and treatment of coronary heart disease, and lifestyle interventions."3.88Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. ( Chamberlain, JJ; Johnson, EL; Leal, S; Peterson, L; Rhinehart, AS; Shubrook, JH, 2018)
"The effect of prior use of aspirin (ASA) on the onset of acute coronary syndrome (ACS) has not been clarified."3.85Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. ( Araki, M; Hada, M; Hamaya, R; Hoshino, M; Ichijo, S; Kakuta, T; Kanaji, Y; Kanno, Y; Lee, T; Matsuda, J; Murai, T; Niida, T; Usui, E; Yonetsu, T, 2017)
"To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia."3.83Effects of low-dose aspirin in subjects with dyslipidemia. ( Chen, J; Lou, G; Xia, Y, 2016)
"To study whether effect of aspirin plus low-dose diethylstilbestrol is more effective and safer than high diethylstilbestrol dose alone on prevention of ovariectomy-induced osteopenia and dyslipidemia."3.79Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. ( Cui, L; Huang, JP; Lin, SE; Wu, LZ; Wu, T, 2013)
"Aspirin treatment may have reduced CVEs within a high CVE risk elderly population subgroup."2.90Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019)
" An additional aim is to assess the effect of the polypill on LDL-c and BP compared to the administration of separate pills of identically dosed components of the polypill."2.79The evening versus morning polypill utilization study: the TEMPUS rationale and design. ( Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R, 2014)
"Aspirin, which has been shown to reduce the local production of gall bladder mucins (mucosal or parietal factors of gallstone formation) in animal experimental models, does not appear to reduce the risk of symptomatic gallstones disease when tested alone."2.48Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. ( Cariati, A; Piromalli, E, 2012)
" There is a need for further research in order to come to a clear conclusion regarding combined therapies of aspirin and laropiprant pretreatment, as well as exact dosage requirements."2.45Mechanisms of flushing due to niacin and abolition of these effects. ( Arora, R; Sood, A, 2009)
"Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life."2.45Psoriasis: an opportunity to identify cardiovascular risk. ( Federman, DG; Gunderson, CG; Kirsner, RS; Prodanovich, S; Shelling, M, 2009)
"The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension."2.43Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006)
"Cardiovascular diseases are the major cause of death and a significant cause of disability in the Western world and more recently threaten to pose an increasing health burden on developing nations."2.43Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions. ( Grewal, J; Lonn, E, 2006)
"In Western European countries, acute ischemic stroke (AIS) remains the third leading cause of death."1.62Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy. ( Freitas-Silva, M; Medeiros, R; Nunes, JPL, 2021)
"7%), all at low dosage levels."1.35[Prescription patterns for antilipidemic drugs in a group of Colombian patients]. ( Machado, JE; Mesa, G; Moncada, JC, 2008)
"But aspirin therapy was used in only 35 cases (32."1.33The rate of checking urine microalbumin and aspirin primary prevention in type 2 DM. ( Limpawattana, P; Mahankkanukrauh, A; Sawanyawisuth, K; Wongvipaporn, C, 2006)

Research

Studies (49)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (36.73)29.6817
2010's28 (57.14)24.3611
2020's3 (6.12)2.80

Authors

AuthorsStudies
Jung, M1
Lee, S1
Han, YM1
Lee, YJ1
Jang, YN1
Kim, HM1
Seo, HS1
Jung, TW1
Jeong, JH1
Freitas-Silva, M1
Medeiros, R1
Nunes, JPL1
Zuo, HJ1
Wang, WH1
Deng, LQ1
Su, JL1
Chamberlain, JJ1
Johnson, EL1
Leal, S1
Rhinehart, AS1
Shubrook, JH1
Peterson, L1
Sugawara, M5
Goto, Y2
Yamazaki, T5
Teramoto, T5
Oikawa, S6
Shimada, K5
Uchiyama, S5
Ando, K5
Ishizuka, N5
Murata, M5
Yokoyama, K5
Uemura, Y2
Ikeda, Y5
Faggiano, P1
Fattirolli, F1
Frisinghelli, A1
Piccioli, L1
Dasseni, N1
Silverii, MV1
Albricci, L1
D'Ambrosio, G1
Garrì, R1
Esposito, L1
Giallauria, F1
Cheng, F1
Li, W1
Zhou, Y1
Li, J1
Shen, J1
Lee, PW1
Tang, Y1
Lin, SE1
Huang, JP1
Wu, LZ1
Wu, T1
Cui, L1
Stolarz-Skrzypek, K1
Bednarski, A1
Drozdz, D1
Czarnecka, D1
Bobolea, I1
Cabañas, R1
Jurado-Palomo, J1
Fiandor, A1
Quirce, S1
De Kam, PJ1
Luo, WL1
Wenning, L1
Ratcliffe, L1
Sisk, CM1
Royalty, J1
Radziszewski, W1
Wagner, JA1
Lai, E1
Barbieri, L1
Verdoia, M1
Schaffer, A1
Marino, P1
De Luca, G1
Paixao, AR1
Enriquez, JR1
Wang, TY1
Li, S1
Berry, JD1
Khera, A1
Das, SR1
de Lemos, JA1
Kontos, MC1
Minematsu, K1
Matsumoto, M1
Hagström, E1
Roe, MT1
Hafley, G1
Neely, ML1
Sidhu, MS1
Winters, KJ1
Prabhakaran, D1
White, HD1
Armstrong, PW1
Fox, KA1
Ohman, EM1
Boden, WE1
Lou, G1
Chen, J1
Xia, Y1
Yonetsu, T1
Lee, T1
Murai, T1
Kanno, Y1
Hamaya, R1
Ichijo, S1
Niida, T1
Hada, M1
Araki, M1
Matsuda, J1
Usui, E1
Hoshino, M1
Kanaji, Y1
Kakuta, T1
Engberding, N1
Wenger, NK1
Federman, DG1
Shelling, M1
Prodanovich, S1
Gunderson, CG1
Kirsner, RS1
Thakkar, RB1
Kashyap, ML1
Lewin, AJ1
Krause, SL1
Jiang, P1
Padley, RJ1
Philipp, S1
Böse, D1
Wijns, W1
Marso, SP1
Schwartz, RS1
König, A1
Lerman, A1
Garcia-Garcia, HM1
Serruys, PW1
Erbel, R1
Sood, A1
Arora, R1
Yamada, N1
Jacobson, TA1
Frisbee, JC1
Goodwill, AG1
Stapleton, PA1
Frisbee, SJ1
d'Audiffret, AC1
Salgado, BJ1
Salgado, JV1
Dos Santos, AM1
Casulari, LA1
Poisson, S1
Johnston, SC1
Yameogo, NV1
Ndiaye, MB1
Mbaye, A1
Bennani, R1
Kagambega, LJ1
Bodian, M1
Diao, M1
Sarr, M1
Kane, A1
Ba, SA1
Shinohara, Y1
Cariati, A1
Piromalli, E1
Ward, DR1
Novak, E1
Scott-Douglas, N1
Brar, S1
White, M1
Hemmelgarn, BR1
Lafeber, M1
Grobbee, DE1
Bots, ML1
Thom, S1
Webster, R1
Rodgers, A1
Visseren, FL1
Spiering, W1
Papp, E1
Havasi, V1
Bene, J1
Komlosi, K1
Czopf, L1
Magyar, E1
Feher, C1
Feher, G1
Horvath, B1
Marton, Z1
Alexy, T1
Habon, T1
Szabo, L1
Toth, K1
Melegh, B1
Haines, ST1
Fuke, DC1
Lender, D1
Rodgers, PT1
Sysko, SK1
Sawanyawisuth, K1
Limpawattana, P1
Mahankkanukrauh, A1
Wongvipaporn, C1
Oberwittler, H1
Baccara-Dinet, M1
Kakafika, AI2
Liberopoulos, EN1
Karagiannis, A2
Athyros, VG2
Mikhailidis, DP2
Lonn, E1
Grewal, J1
Kurukulasuriya, LR1
Govindarajan, G1
Sowers, J1
Kotake, H1
Berry, C1
Tardif, JC1
Bourassa, MG1
Liao, JK1
Faraday, N1
Yanek, LR1
Mathias, R1
Herrera-Galeano, JE1
Vaidya, D1
Moy, TF1
Fallin, MD1
Wilson, AF1
Bray, PF1
Becker, LC1
Becker, DM1
Tziomalos, K1
Pagourelias, ED1
Skaperdas, A1
Hatzitolios, A1
Machado, JE1
Moncada, JC1
Mesa, G1
Masanauskiene, E1
Naudziūnas, A1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Impact of Meal Timing on Neurovascular Control in Adults[NCT04133701]34 participants (Actual)Interventional2022-02-02Completed
Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849]Phase 410,000 participants Interventional2005-03-31Recruiting
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia[NCT01012219]Phase 136 participants (Actual)Interventional2009-11-30Completed
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]Phase 42,200 participants (Actual)Interventional2016-04-30Completed
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268]Phase 472 participants (Actual)Interventional2019-04-24Completed
Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease[NCT03757156]4,118 participants (Anticipated)Interventional2019-03-31Not yet recruiting
Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia[NCT00626392]Phase 3277 participants (Actual)Interventional2008-02-29Completed
A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill[NCT01506505]78 participants (Actual)Interventional2012-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cutaneous Bleeding Time (BT)

"Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days.~The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable.~Period 3 was not analyzed as bleeding time was not an objective for this part of the study." (NCT01012219)
Timeframe: Day 8

InterventionSeconds (Least Squares Mean)
Clopidogrel + Aspirin +Laropiprant478
Clopidogrel + Aspirin389

Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe. (NCT00626392)
Timeframe: 4 weeks

InterventionNumber of Events per Subject per Week (Mean)
Any Acetylsalicylic Acid0.3
No Acetylsalicylic Acid0.8

Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily. (NCT00626392)
Timeframe: 4 weeks

InterventionScores on a Scale (Mean)
Any Acetylsalicylic Acid3.1
No Acetylsalicylic Acid5.1

Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment

The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated. (NCT00626392)
Timeframe: From Baseline to end of Week 1

,
InterventionPercentage of Subjects (Number)
NoneMildNone/mildModerateSevereVery severe
Any Acetylsalicylic Acid5728851141
No Acetylsalicylic Acid4824711784

Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated. (NCT00626392)
Timeframe: 4 weeks

,
InterventionPercentage of Subjects (Number)
NoneMildNone/MildModerateSevereVery severe
Any Acetylsalicylic Acid30285828114
No Acetylsalicylic Acid151430352313

Reviews

17 reviews available for aspirin and Dyslipidemia

ArticleYear
[Prevention of atherosclerosis in children--the role of statins and aspirin].
    Przeglad lekarski, 2013, Volume: 70, Issue:2

    Topics: Adult; Aspirin; Atherosclerosis; Child; Comorbidity; Diabetes Mellitus; Dyslipidemias; Humans; Hydro

2013
Cardiovascular disease prevention tailored for women.
    Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Choleste

2008
Psoriasis: an opportunity to identify cardiovascular risk.
    The British journal of dermatology, 2009, Volume: 160, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; F

2009
Mechanisms of flushing due to niacin and abolition of these effects.
    Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:11

    Topics: Aspirin; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hypolipidemic Agents; Indoles; Nia

2009
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
    Mayo Clinic proceedings, 2010, Volume: 85, Issue:4

    Topics: Aspirin; Attitude to Health; Coronary Disease; Delayed-Action Preparations; Dose-Response Relationsh

2010
Prevention of stroke following transient ischemic attack.
    Current atherosclerosis reports, 2011, Volume: 13, Issue:4

    Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Clin

2011
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H

2010
Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:9

    Topics: Administration, Oral; Animals; Aspirin; Atherosclerosis; Cardiovascular Agents; Cholecystolithiasis;

2012
Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment.
    International journal of clinical practice, 2006, Volume: 60, Issue:6

    Topics: Aspirin; Dose-Response Relationship, Drug; Dyslipidemias; Flushing; Humans; Hypolipidemic Agents; Ni

2006
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
    Current vascular pharmacology, 2006, Volume: 4, Issue:3

    Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac

2006
Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
    Current vascular pharmacology, 2006, Volume: 4, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Atheroscler

2006
Stroke prevention in diabetes and obesity.
    Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular

2006
[Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:11

    Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Dyslipidemias; Humans; Hy

2006
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.
    Journal of the American College of Cardiology, 2007, Feb-13, Volume: 49, Issue:6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Disease; Diabetes

2007
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
    Circulation, 2007, Mar-27, Volume: 115, Issue:12

    Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr

2007
Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:14

    Topics: Aspirin; Drug Combinations; Dyslipidemias; Health Services Needs and Demand; Humans; Hydroxymethylgl

2007
[Peripheral arterial disease--an underappreciated clinical problem].
    Medicina (Kaunas, Lithuania), 2008, Volume: 44, Issue:4

    Topics: Age Factors; Aged; Ankle; Aspirin; Atherosclerosis; Brachial Artery; Diabetes Complications; Dyslipi

2008

Trials

10 trials available for aspirin and Dyslipidemia

ArticleYear
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:3

    Topics: Aged; Asian People; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidem

2019
The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
    Platelets, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aspirin; Clopidogrel; Cross-Over Studies; Double-Blind Method; Drug Interactions; Dysli

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
    Stroke, 2016, Volume: 47, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Comorbidity; Diabetes Mellitus; Dyslipidemias; Fem

2016
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
    Clinical cardiology, 2016, Volume: 39, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel;

2016
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aspirin; Delayed-Action Preparations; Dose-Response Relationship,

2009
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
    American heart journal, 2010, Volume: 159, Issue:3

    Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cohort Studies; Diabetes Mellitus; Dose-Response Rel

2010
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
    Minerva cardioangiologica, 2010, Volume: 58, Issue:5

    Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidem

2010
Assessment of the Siksika chronic disease nephropathy-prevention clinic.
    Canadian family physician Medecin de famille canadien, 2013, Volume: 59, Issue:1

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bl

2013
The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    European journal of preventive cardiology, 2014, Volume: 21, Issue:4

    Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Biomarkers; Blood Platelets; Blood Pressure;

2014

Other Studies

22 other studies available for aspirin and Dyslipidemia

ArticleYear
Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea.
    Drugs & aging, 2020, Volume: 37, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2

2020
Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR
    BioMed research international, 2020, Volume: 2020

    Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Atherosclerosis; Dyslipidemias; Hep G2 Cells; Human

2020
Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy.
    Clinical neurology and neurosurgery, 2021, Volume: 203

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Dyslipidemias; F

2021
Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing.
    Journal of the American Society of Hypertension : JASH, 2018, Volume: 12, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Beijing; Blood Glucose; Cholesterol, LDL; Cross-Sectional S

2018
Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
    Annals of internal medicine, 2018, 05-01, Volume: 168, Issue:9

    Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure Monitoring, Ambulatory; Coronary Disease; Di

2018
Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
    Journal of hypertension, 2019, Volume: 37, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Pressure; Diabetes Mellitus; Dyslipidemias; Female; Hemorrha

2019
Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2019, 05-20, Volume: 89, Issue:2

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases;

2019
Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs).
    Molecular bioSystems, 2013, Volume: 9, Issue:6

    Topics: Arrhythmias, Cardiac; Aspirin; Benzhydryl Compounds; Bradycardia; Computer Simulation; Databases, Ch

2013
Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol.
    Biomedical and environmental sciences : BES, 2013, Volume: 26, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Weight; Bone and Bones;

2013
Concurrent coxibs and anti-platelet therapy unmasks aspirin-exacerbated respiratory disease.
    The European respiratory journal, 2013, Volume: 42, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 2 Inhibitors; Dyslipi

2013
[Two catheters for one coronary perforation].
    Giornale italiano di cardiologia (2006), 2015, Volume: 16, Issue:2

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Cardiac Ca

2015
Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR.
    American heart journal, 2015, Volume: 170, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidemias; Female; Guideline Adherenc

2015
Effects of low-dose aspirin in subjects with dyslipidemia.
    Lipids in health and disease, 2016, Jun-16, Volume: 15

    Topics: Adult; Aspirin; C-Reactive Protein; Cholesterol, LDL; Convalescence; Coronary Angiography; Coronary

2016
Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography.
    Circulation journal : official journal of the Japanese Circulation Society, 2017, Mar-24, Volume: 81, Issue:4

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Aspirin; Case-Control Studies; Dyslipidemias; Female; Hu

2017
Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry.
    European heart journal, 2010, Volume: 31, Issue:2

    Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetic Angiopathies; Dyslipidemias

2010
Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation.
    Physiological genomics, 2010, Volume: 42, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Apolipoproteins E; Arterioles; Aspirin; Blo

2010
[Myocardial infarction in the young adult--retrospective analysis of cases compile at the University Hospital of Dakar].
    The Pan African medical journal, 2010, Volume: 6

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Contraceptive

2010
Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:6

    Topics: Adult; Aged; Alleles; Aspirin; Drug Resistance; Dyslipidemias; Female; Gene Frequency; Genotype; Hum

2005
Evaluating and treating cardiometabolic risk factors: a case discussion.
    Pharmacotherapy, 2006, Volume: 26, Issue:5 Pt 2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diet; Dyslipidemias; Exercise; Female; Heart Dise

2006
The rate of checking urine microalbumin and aspirin primary prevention in type 2 DM.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:5

    Topics: Albuminuria; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hyp

2006
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.
    Circulation, 2007, May-15, Volume: 115, Issue:19

    Topics: Adult; Arachidonic Acid; Aspirin; beta-Thromboglobulin; Black or African American; Blood Platelets;

2007
[Prescription patterns for antilipidemic drugs in a group of Colombian patients].
    Revista panamericana de salud publica = Pan American journal of public health, 2008, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antihypertensive Agents

2008